OC-0562: Exploiting tumor DNA repair status and hypoxia with CP-506, a novel hypoxia-activated prodrug. (November 2020) - Van der Wiel, A.; Marcus, D.; Niemans, R.; Yaromina, A.; Theys, J.; Mowday, A.; Ashoorzadeh, A.; Anderson, R.; Bull, M.; Abbattista, M.; Heyerick, A.; Guise, C.; et al.